This invention relates to medical instruments and systems for applying energy to tissue, and more particularly relates to a system for ablating, sealing, welding, coagulating, shrinking or creating lesions in tissue by means of contacting a targeted region of tissue in a patient with a vapor phase media wherein a subsequent vapor-to-liquid phase change of the media applies thermal energy to the tissue to cause an intended therapeutic effect. Variations of the invention include devices and methods for generating a flow of high quality vapor and monitoring the vapor flow for various parameters with one or more sensors. In yet additional variations, the invention includes devices and methods for modulating parameters of the system in response to the observed parameters.
Various types of medical instruments utilizing radiofrequency (Rf) energy, laser energy, microwave energy and the like have been developed for delivering thermal energy to tissue, for example to ablate tissue. While such prior art forms of energy delivery work well for some applications, Rf, laser and microwave energy typically cannot cause highly “controlled” and “localized” thermal effects that are desirable in controlled ablation soft tissue for ablating a controlled depth or for the creation of precise lesions in such tissue. In general, the non-linear or non-uniform characteristics of tissue affect electromagnetic energy distributions in tissue.
What is needed are systems and methods that controllably apply thermal energy in a controlled and localized manner without the lack of control often associated when Rf, laser and microwave energy are applied directly to tissue.
The present invention is adapted to provide improved methods of controlled thermal energy delivery to localized tissue volumes, for example for ablating, sealing, coagulating or otherwise damaging targeted tissue, for example to ablate a tissue volume interstitially or to ablate the lining of a body cavity. Of particular interest, the method causes thermal effects in targeted tissue without the use of Rf current flow through the patient's body and without the potential of carbonizing tissue. The devices and methods of the present disclosure allow the use of such energy modalities to be used as an adjunct rather than a primary source of treatment.
One variation of the present novel method includes a method of delivering energy into a target tissue of a body region, the method comprising advancing a working end of a device into the body region, expanding a structure from within a working end of the device into the body region, where at least a portion of the thin wall structure is permeable to allow transfer of a medium through the structure to the tissue, and delivering an amount of energy from the structure to treat the target tissue of the body region.
Expanding the structure can include everting the structure. Although the variations described below discuss everting the structure, alternate variations can include inflating, unfolding, unfurling or unrolling the structure. Typically, these different expansion modes relate to the manner in which the structure is located (partially or fully) within the working end of the device. In any case, many variations of the method and device allow for the structure to expand to (or substantially) to the cavity or tissue region being treated. As such, the structure can comprise a thin wall structure or other structure that allows for delivery of the vapor media therethrough. Expansion of the structure can occur using a fluid or gas. Typically the expansion pressure is low, however, alternate variations can include the use of high pressure expansion. In such a variation, the expansion of the structure can be used to perform a therapeutic treatment in conjunction with the energy delivery.
Typically, the energy applied by the vapor media is between 25 W and 150 W. In additional variations, the vapor media can apply a first amount of energy with alternate energy modalities being used to provide additional amounts of energy as required by the particular application or treatment. Such additional energy modalities include RF energy, light energy, radiation, resistive heating, chemical energy and/or microwave energy. In some cases, the treatment ablates the target tissue. In alternate variations, the treatment coagulates or heats the tissue to affect a therapeutic purpose. The additional modalities of energy can be applied from elements that are in the expandable structure or on a surface of the structure.
Turning now to the vapor delivery, as described below, the vapor transfers an amount of energy to the tissue without charring or desiccating the tissue. In certain variations, delivering the amount of energy comprises delivering energy using a vapor media by passing the vapor media through the structure. Accordingly, the expandable structure can include at least one vapor outlet. However, additional variations of the method or device can include structures that include a plurality of permeable portions, where at least a porosity of one of the permeable portion varies such that delivery of the amount of energy is non-uniform about the structure when expanded. In one example, delivering the amount of energy comprises delivering a first amount of energy at a central portion of the structure when expanded and a second amount of energy at a distal or proximal portion, and where the first amount of energy is different than the second amount of energy.
In those variations that employ additional energy delivery means, a second amount of energy can be delivered from a portion of the structure. For example, electrodes, antennas, or emitters, can be positioned on or within the structure.
The structures included within the scope of the methods and devices described herein can include any shape as required by the particular application. Such shapes include, but are not limited to round, non-round, flattened, cylindrical, spiraling, pear-shaped, triangular, rectangular, square, oblong, oblate, elliptical, banana-shaped, donut-shaped, pancake-shaped or a plurality or combination of such shapes when expanded. The shape can even be selected to conform to a shape of a cavity within the body (e.g., a passage of the esophagus, a chamber of the heart, a portion of the GI tract, the stomach, blood vessel, lung, uterus, cervical canal, fallopian tube, sinus, airway, gall bladder, pancreas, colon, intestine, respiratory tract, etc.)
In additional variations, the devices and methods described herein can include one or more additional expanding members. Such additional expanding members can be positioned at a working end of the device. The second expandable member can include a surface for engaging a non-targeted region to limit the energy from transferring to the non-targeted region. The second expandable member can be insulated to protect the non-targeted region. Alternatively, or in combination, the second expandable member can be expanded using a cooling fluid where the expandable member conducts cooling to the non-targeted region. Clearly, any number of additional expandable members can be used. In one variation, an expandable member can be used to seal an opening of the cavity.
In certain variations, the device or method includes the use of one or more vacuum passages so that upon monitoring a cavity pressure within the cavity, to relieve pressure when the cavity pressure reaches a pre-determined value.
In another variation, a device according to the present disclosure can include an elongated device having an axis and a working end, a vapor source communicating with at least one vapor outlet in the working end, the vapor source providing a condensable vapor through the vapor outlet to contact the targeted tissue region, such that when the condensable vapor contacts the targeted tissue region, an amount of energy transfers from the condensable vapor to the targeted tissue region, and at least one expandable member is carried by the working end, the expandable member having a surface for engaging a non-targeted tissue region to limit contact and energy transfer between the condensable vapor and the non-targeted tissue region.
In one variation a first and second expandable members are disposed axially proximal of the at least one vapor outlet. This allows treatment distal to the expandable members. In another variation, at least one vapor outlet is intermediate the first and second expandable members. Therefore, the treatment occurs between the expandable members. In yet another variation, at least one expandable member is radially positioned relative to at least one vapor outlet to radially limit the condensable vapor from engaging the non-targeted region.
In additional variation of the methods and devices, the expandable member(s) is fluidly coupled to a fluid source for expanding the expandable member. The fluid source can optionally comprise a cooling fluid that allows the expandable member to cool tissue via conduction through the surface of the expandable member.
In another variation of a method under the principles of the present invention, the method includes selectively treating a target region of tissue and preserving a non-target region of tissue within a body region. For example, the method can include introducing a working end of an axially-extending vapor delivery tool into cavity or lumen, the working end comprising at least one vapor outlet being fluidly coupleable to a vapor source having a supply of vapor, expanding at least one expandable member carried by the working end to engage the non-target region of tissue, and delivering the vapor through the vapor outlet to the target region tissue to cause energy exchange between the vapor and the target region tissue such that vapor contact between the non-target region of tissue is minimized or prevented by the at least one expanding member.
The methods described herein can also include a variation of treating esophageal tissue of a patient's body. In such a case, any of the variations of the devices described herein can be used. In any case, an example of the method includes introducing an elongate vapor delivery tool into an esophageal passage, the vapor delivery tool being coupleable to a supply of vapor, delivering the vapor through the delivery tool into the passage, and controlling energy application to a surface of the passage by controlling interaction between the vapor and the surface of the passage. In an additional variation, the elongate vapor delivery tool includes a vapor lumen and a vacuum lumen, where the vapor lumen and vacuum lumen are in fluid communication, where controlling interaction between the vapor and the surface of the passage comprises modulating delivery of a vapor inflow through the vapor lumen and modulating vacuum outflow through the vacuum lumen. The method can further include applying a cooling media to the surface of the passage to limit diffusion of heat in the surface.
Methods of the present disclosure also include methods of reducing diabetic conditions. For example, the method can include treating a patient to reduce diabetic conditions by inserting a vapor delivery device to an digestive passage, where the vapor delivery device is coupleable to a source of vapor, delivering the vapor to a wall of the digestive tract to transfer energy from the vapor to the wall in a sufficient amount to alter a function of the digestive tract, and controlling interaction between the vapor and the wall to cause controlled ablation at the a treatment area. The treatment can be applied in an organ selected from the group consisting of the stomach, the small intestines, the large intestines, and the duodenum. In some variations, controlling interaction between the vapor and the wall causes a thin ablation layer on a surface of the wall.
The present disclosure also includes medical systems for applying thermal energy to tissue, where the system comprises an elongated probe with an axis having an interior flow channel extending to at least one outlet in a probe working end; a source of vapor media configured to provide a vapor flow through at least a portion of the interior flow channel, wherein the vapor has a minimum temperature; and at least one sensor in the flow channel for providing a signal of at least one flow parameter selected from the group one of (i) existence of a flow of the vapor media, (ii) quantification of a flow rate of the vapor media, and (iii) quality of the flow of the vapor media. The medical system can include variations where the minimum temperature varies from at least 80° C., 100° C. 120° C., 140° C. and 160° C. However, other temperature ranges can be included depending upon the desired application.
Sensors included in the above system include temperature sensor, an impedance sensor, a pressure sensor as well as an optical sensor.
The source of vapor media can include a pressurized source of a liquid media and an energy source for phase conversion of the liquid media to a vapor media. In addition, the medical system can further include a controller capable of modulating a vapor parameter in response to a signal of a flow parameter; the vapor parameter selected from the group of (i) flow rate of pressurized source of liquid media, (ii) inflow pressure of the pressurized source of liquid media, (iii) temperature of the liquid media, (iv) energy applied from the energy source to the liquid media, (v) flow rate of vapor media in the flow channel, (vi) pressure of the vapor media in the flow channel, (vi) temperature of the vapor media, and (vii) quality of vapor media.
In another variation, a novel medical system for applying thermal energy to tissue comprises an elongated probe with an axis having an interior flow channel extending to at least one outlet in a probe working end, wherein a wall of the flow channel includes an insulative portion having a thermal conductivity of less than a maximum thermal conductivity; and a source of vapor media configured to provide a vapor flow through at least a portion of the interior flow channel, wherein the vapor has a minimum temperature.
Variations of such systems include systems where the maximum thermal conductivity ranges from 0.05 W/mK, 0.01 W/mK and 0.005 W/mK.
Methods are disclosed herein for thermally treating tissue by providing a probe body having a flow channel extending therein to an outlet in a working end, introducing a flow of a liquid media through the flow channel and applying energy to the tissue by inductively heating a portion of the probe sufficient to vaporize the flowing media within the flow channel causing pressurized ejection of the media from the outlet to the tissue.
The methods can include applying energy between 10 and 10,000 Joules to the tissue from the media. The rate at which the media flows can be controlled as well.
In another variation, the methods described herein include inductively heating the portion of the probe by applying an electromagnetic energy source to a coil surrounding the flow channel. The electromagnetic energy can also inductively heat a wall portion of the flow channel.
Another variation of the method includes providing a flow permeable structure within the flow channel. Optionally, the coil described herein can heat the flow permeable structure to transfer energy to the flow media. Some examples of a flow permeable structure include woven filaments, braided filaments, knit filaments, metal wool, a microchannel structure, a porous structure, a honeycomb structure and an open cell structure. However, any structure that is permeable to flow can be included.
The electromagnetic energy source can include an energy source ranging from a 10 Watt source to a 500 Watt source.
Medical systems for treating tissue are also described herein. Such systems can include a probe body having a flow channel extending therein to an outlet in a working end, a coil about at least a portion or the flow channel, and an electromagnetic energy source coupled to the coil, where the electromagnetic energy source induces current in the coil causing energy delivery to a flowable media in the flow channel. The systems can include a source of flowable media coupled to the flow channel. The electromagnetic energy source can be capable of applying energy to the flowable media sufficient to cause a liquid-to-vapor phase change in at least a portion of the flowable media as described in detail herein. In addition the probe can include a sensor selected from a temperature sensor, an impedance sensor, a capacitance sensor and a pressure sensor. In some variations the probe is coupled to an aspiration source.
The medical system can also include a controller capable of modulating at least one operational parameter of the source of flowable media in response to a signal from a sensor. For example, the controller can be capable of modulating a flow of the flowable media. In another variation, the controller is capable of modulating a flow of the flowable media to apply between 100 and 10,000 Joules to the tissue.
The systems described herein can also include a metal portion in the flow channel for contacting the flowable media. The metal portion can be a flow permeable structure and can optionally comprise a microchannel structure. In additional variations, the flow permeable structure can include woven filaments, braided filaments, knit filaments, metal wool, a porous structure, a honeycomb structure, an open cell structure or a combination thereof.
In another variation, the methods described herein can include positioning a probe in an interface with a targeted tissue, and causing a vapor media from to be ejected from the probe into the interface with tissue wherein the media delivers energy ranging from 5 joules to 100,000 joules to cause a therapeutic effect, wherein the vapor media is converted from a liquid media within the probe by inductive heating means.
Methods described herein also include methods of treating tissue by providing medical system including a heat applicator portion for positioning in an interface with targeted tissue, and converting a liquid media into a vapor media within an elongated portion of the medical system having a flow channel communicating with a flow outlet in the heat applicator portion, and contacting the vapor media with the targeted tissue to thereby deliver energy ranging from 5 joules to 100,000 joules to cause a therapeutic effect.
As discussed herein, the methods can include converting the liquid into a vapor media using an inductive heating means. In an alternate variation, a resistive heating means can be combined with the inductive heating means or can replace the inductive heating means.
The instrument and method of the invention can cause an energy-tissue interaction that is imagable with intra-operative ultrasound or MRI.
The instrument and method of the invention cause thermal effects in tissue that do not rely applying an electrical field across the tissue to be treated.
Additional advantages of the invention will be apparent from the following description, the accompanying drawings and the appended claims.
All patents, patent applications and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
In addition, it is intended that combinations of aspects of the systems and methods described herein as well as the various embodiments themselves, where possible, are within the scope of this disclosure.
This application is related to the following U.S Non-provisional and Provisional applications: Application No. 61/126,647 Filed on May 6, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/126,651 Filed on May 6, 2008 MEDICAL SYSTEM AND METHOD OF USE; U.S. Application No. 61/126,612 Filed on May 6, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/126,636 Filed on May 6, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/130,345 Filed on May 31, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/066,396 Filed on Feb. 20, 2008 TISSUE ABLATION SYSTEM AND METHOD OF USE; Application No. 61/123,416 Filed on Apr. 8, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/068,049 Filed on Mar. 4, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/123,384 Filed on Apr. 8, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/068,130 Filed on Mar. 4, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/123,417 Filed on Apr. 8, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/123,412 Filed on Apr. 8, 2008 MEDICAL SYSTEM AND METHOD OF USE; Application No. 61/126,830 Filed on May 7, 2008 MEDICAL SYSTEM AND METHOD OF USE; and Application No. 61/126,620 Filed on May 6, 2008 MEDICAL SYSTEM AND METHOD OF USE.
The systems and methods described herein are also related to U.S. patent application Ser. No. 10/681,625 filed Oct. 7, 2003 titled “Medical Instruments and Techniques for Thermally-Mediated Therapies”; Ser. No. 11/158,930 filed Jun. 22, 2005 titled “Medical Instruments and Techniques for Treating Pulmonary Disorders”; Ser. No. 11/244,329 filed Oct. 5, 2005 titled “Medical Instruments and Methods of Use” and Ser. No. 11/329,381 filed Jan. 10, 2006 titled “Medical Instrument and Method of Use”.
All of the above applications are incorporated herein by this reference and made a part of this specification, together with the specifications of all other commonly-invented applications cited in the above applications.
As used in the specification, “a” or “an” means one or more. As used in the claim(s), when used in conjunction with the word “comprising”, the words “a” or “an” mean one or more. As used herein, “another” means as least a second or more. “Substantially” or “substantial” mean largely but not entirely. For example, substantially may mean about 10% to about 99.999, about 25% to about 99.999% or about 50% to about 99.999%.
In general, the thermally-mediated treatment method comprises causing a vapor-to-liquid phase state change in a selected media at a targeted tissue site thereby applying thermal energy substantially equal to the heat of vaporization of the selected media to the tissue site. The thermally-mediated therapy can be delivered to tissue by such vapor-to-liquid phase transitions, or “internal energy” releases, about the working surfaces of several types of instruments for ablative treatments of soft tissue.
It has been found that the controlled application of such energy in a controlled media-tissue interaction solves many of the vexing problems associated with energy-tissue interactions in Rf, laser and ultrasound modalities. The apparatus of the invention provides a vaporization chamber in the interior of an instrument, in an instrument's working end or in a source remote from the instrument end. A source provides liquid media to the interior vaporization chamber wherein energy is applied to create a selected volume of vapor media. In the process of the liquid-to-vapor phase transition of a liquid media, for example water, large amounts of energy are added to overcome the cohesive forces between molecules in the liquid, and an additional amount of energy is required to expand the liquid 1000+ percent (PAD) into a resulting vapor phase (see
In
Treatment Liquid Source, Energy Source, Controller
Referring to
As can be seen in
In one embodiment shown in
As can be seen in
In another embodiment, still referring to
In
Now turning to
In one embodiment, the outer diameter of extension portion 105 or working end 110 is, for example, 0.2 mm, 0.5 mm, 1 mm, 2 mm, 5 mm or an intermediate, smaller or larger diameter. Optionally, the outlets can comprise microporosities 177 in a porous material as illustrated in
In an exemplary embodiment as shown in
In other embodiments, the working end 110 can comprise needles with terminal outlets or side outlets as shown in
In another embodiment of
In another embodiment of
Sensors for Vapor Flows, Temperature, Pressure, Quality
Referring to
Still referring to
Another embodiment of sensor system 175 in a similar working end 110 is depicted in
Inductive Vapor Generation Systems
In
In general, the system of the invention provides a small handheld device including an assembly that utilized electromagnetic induction to turn a sterile water flow into superheated or dry vapor which can is propagated from at least one outlet in a vapor delivery tool to interface with tissue and thus ablate tissue. In one aspect of the invention, an electrically-conducting microchannel structure or other flow-permeable structure is provided and an inductive coil causes electric current flows in the structure. Eddies within the current create magnetic fields, and the magnetic fields oppose the change of the main field thus raising electrical resistance and resulting in instant heating of the microchannel or other flow-permeable structure. In another aspect of the invention, it has been found that corrosion-resistant microtubes of low magnetic 316 SS are best suited for the application, or a sintered microchannel structure of similar material. While magnetic materials can improve the induction heating of a metal because of ferromagnetic hysteresis, such magnetic materials (e.g. carbon steel) are susceptible to corrosion and are not optimal for generating vapor used to ablate tissue. In certain embodiments, the electromagnetic energy source 440 is adapted for inductive heating of a microchannel structure with a frequency in the range of 50 kHz to 2 Mhz, and more preferably in the range of 400 kHz to 500 kHz. While a microchannel structure is described in more detail below, it should be appreciated that the scope of the invention includes flow-permeable conductive structures selected from the group of woven filaments structures, braided filament structures, knit filaments structures, metal wool structures, porous structures, honeycomb structures and an open cell structures.
In general, a method of the invention comprises utilizing an inductive heater 420 of
In one embodiment shown schematically in
Now turning to
The region containing the target tissue includes any space, cavity, passage, opening, lumen or potential space in a body such as a sinus, airway, blood vessel, uterus, joint capsule, GI tract lumen or respiratory tract lumen. As can be seen in
In general, a method of the invention as in
The elongated catheter or extension member 610 has a first end or handle end 612 that is coupled to extension member 610 that extends to working end 615. The extension member 610 has a diameter and length suitable for either a nasal or oral introduction into the esophagus 616. The working end 615 of the extension member is configured with a plurality of expandable structures such as temperature resistant occlusion balloons 620A, 620B, 620C and 620D. In one embodiment, the balloons can be complaint silicone. In other embodiment, the balloons can be non-compliant thin film structures. The handle end 612 includes a manifold 622 that couples to multiple lumens to a connector 625 that allows for each balloon 620A, 620B, 620C and 620D to be expanded independently, for example, with a gas or liquid inflation source indicated at 630. The inflation source 630 can be a plurality of syringes, or a controller can be provided to automatically pump a fluid to selected balloons. The number of balloons carried by extension member 610 can range from 2 to 10 or more. As can be understood in
Still referring to
The method can include the delivery of vapor for less than 30 seconds, less than 20 seconds, less than 10 seconds or less than 5 seconds to accomplish the ablation. The vapor quality as described above can be greater than 70%, 80% or 90% and can uniformly ablate the surface of the esophageal lining to a depth of up to 1.0 mm.
In another optional aspect of the invention also shown in
In general, a method of the invention for ablating or coagulating tissue comprises introducing a device proximate to a targeted tissue in a body cavity such as a bleeding stomach ulcer and thermally treating the a targeted ulcer with vapor media introduced by the device. In this method, the thermal treatment is provided by a release of energy from a phase change of a vapor media, which can comprise water vapor. However, additional methods can include treatment of any body tissue using the methods and procedures described herein.
In general, a method corresponding to the invention for localized ablation of a targeted region of a wall of an organ, vessel, cavity or lumen comprises positioning a device working end proximate to a targeted tissue of the wall of a body organ, cavity, vessel or lumen, and introducing a flow media to the vicinity of the targeted tissue wherein a release of energy from a phase change of a water vapor portion of the flow media ablates the targeted tissue. The method can include delivering the flow media about a surface of the targeted tissue, injecting the flow media into subsurface portion of the targeted tissue, or both. In one method, the flow media is delivered in device working end is expandable and configures to contain the flow media. In another method, the working end is configured to contain and circulate the flow media between an outlet and an inlet port carried in the working end. In one method, a filter member is provided to prevent ablation detritus from entering the inlet port. By this means, the vapor media can provide a phase change energy release about or distal to the filter member to interface with, and ablate, the targeted tissue engaged by the working end. The method can target any tissue in a body cavity or lumen, as malignant tumors, benign tumors and growths, ulcers, polyps, fibroids, lesions, nodules, dysplasia or a bleeding surface of a tissue, organ, bone, body cavity or other body structure.
Although particular embodiments of the present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration and the above description of the invention is not exhaustive. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.
This application claims benefit of U.S. Provisional Application No. 61/291,315 filed on Dec. 30, 2009 and titled MEDICAL SYSTEM AND METHOD OF USE the entirety of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
408899 | Bioch et al. | Aug 1889 | A |
697181 | Smith | Apr 1902 | A |
1719750 | Bridge et al. | Sep 1927 | A |
3818913 | Wallach | Jun 1974 | A |
3880168 | Berman | Apr 1975 | A |
3930505 | Wallach | Jan 1976 | A |
4024866 | Wallach | May 1977 | A |
4083077 | Knight et al. | Apr 1978 | A |
4447227 | Kotsanis | May 1984 | A |
4672962 | Hershenson | Jun 1987 | A |
4682596 | Bales et al. | Jul 1987 | A |
4748979 | Hershenson | Jun 1988 | A |
4773410 | Blackmer et al. | Sep 1988 | A |
4793352 | Eichenlaub | Dec 1988 | A |
4872920 | Flynn et al. | Oct 1989 | A |
4898574 | Uchiyama et al. | Feb 1990 | A |
4915113 | Holman | Apr 1990 | A |
4950266 | Sinofsky | Aug 1990 | A |
4985027 | Dressel | Jan 1991 | A |
5006119 | Acker et al. | Apr 1991 | A |
5011566 | Hoffman | Apr 1991 | A |
5078736 | Behl | Jan 1992 | A |
5084043 | Hertzmann et al. | Jan 1992 | A |
5102410 | Dressel | Apr 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5122138 | Manwaring | Jun 1992 | A |
5158536 | Sekins et al. | Oct 1992 | A |
5162374 | Mulieri et al. | Nov 1992 | A |
5190539 | Fletcher et al. | Mar 1993 | A |
5217459 | Kamerling | Jun 1993 | A |
5217465 | Steppe | Jun 1993 | A |
5263951 | Spears et al. | Nov 1993 | A |
5277696 | Hagen | Jan 1994 | A |
5298298 | Hoffman | Mar 1994 | A |
5306274 | Long | Apr 1994 | A |
5318014 | Carter | Jun 1994 | A |
5331947 | Shturman | Jul 1994 | A |
5334190 | Seiler | Aug 1994 | A |
5344397 | Heaven et al. | Sep 1994 | A |
5348551 | Spears et al. | Sep 1994 | A |
5352512 | Hoffman | Oct 1994 | A |
5417686 | Peterson et al. | May 1995 | A |
5424620 | Cheon et al. | Jun 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5433739 | Sluijter | Jul 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5503638 | Cooper et al. | Apr 1996 | A |
5524620 | Rosenschein | Jun 1996 | A |
5529076 | Schachar | Jun 1996 | A |
5542928 | Evans et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5554172 | Horner et al. | Sep 1996 | A |
5562608 | Sekins et al. | Oct 1996 | A |
5575803 | Cooper et al. | Nov 1996 | A |
5584872 | LaFontaine et al. | Dec 1996 | A |
5591157 | Hennings et al. | Jan 1997 | A |
5591162 | Fletcher et al. | Jan 1997 | A |
5616120 | Andrew et al. | Apr 1997 | A |
5620440 | Heckele et al. | Apr 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5669907 | Platt, Jr. et al. | Sep 1997 | A |
5681282 | Eggers et al. | Oct 1997 | A |
5683366 | Eggers et al. | Nov 1997 | A |
5695507 | Auth et al. | Dec 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5697536 | Eggers et al. | Dec 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5697909 | Eggers et al. | Dec 1997 | A |
5700262 | Acosta et al. | Dec 1997 | A |
5707352 | Sekins et al. | Jan 1998 | A |
5735811 | Brisken | Apr 1998 | A |
5741247 | Rizoiu et al. | Apr 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5752965 | Francis et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5782914 | Schankereli | Jul 1998 | A |
5785521 | Rizoiu et al. | Jul 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5810764 | Eggers et al. | Sep 1998 | A |
5824703 | Clark, Jr. | Oct 1998 | A |
5827268 | Laufer | Oct 1998 | A |
5836896 | Rosenschein | Nov 1998 | A |
5843019 | Eggers et al. | Dec 1998 | A |
5843073 | Sinofsky | Dec 1998 | A |
5871469 | Eggers et al. | Feb 1999 | A |
5879329 | Ginsburg | Mar 1999 | A |
5885243 | Capetan et al. | Mar 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5891095 | Eggers et al. | Apr 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5913856 | Chia et al. | Jun 1999 | A |
5938660 | Swartz et al. | Aug 1999 | A |
5944686 | Patterson et al. | Aug 1999 | A |
5944715 | Goble et al. | Aug 1999 | A |
5957919 | Laufer | Sep 1999 | A |
5964752 | Stone | Oct 1999 | A |
5968037 | Rizoiu | Oct 1999 | A |
5980504 | Sharkey et al. | Nov 1999 | A |
5986662 | Argiro et al. | Nov 1999 | A |
5989212 | Sussman et al. | Nov 1999 | A |
5989238 | Ginsburg | Nov 1999 | A |
5989249 | Kirwin | Nov 1999 | A |
5989445 | Wise et al. | Nov 1999 | A |
5997499 | Sussman et al. | Dec 1999 | A |
6024095 | Stanley, III | Feb 2000 | A |
6024733 | Eggers et al. | Feb 2000 | A |
6027501 | Goble et al. | Feb 2000 | A |
6032077 | Pomeranz | Feb 2000 | A |
6032674 | Eggers et al. | Mar 2000 | A |
6047700 | Eggers et al. | Apr 2000 | A |
6053909 | Shadduck | Apr 2000 | A |
6056746 | Goble et al. | May 2000 | A |
6059011 | Giolo | May 2000 | A |
6063079 | Hovda et al. | May 2000 | A |
6063081 | Mulier et al. | May 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6066139 | Ryan et al. | May 2000 | A |
6074358 | Andrew et al. | Jun 2000 | A |
6080128 | Sussman et al. | Jun 2000 | A |
6080151 | Swartz et al. | Jun 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6095149 | Sharkey et al. | Aug 2000 | A |
6099251 | LaFleur | Aug 2000 | A |
6102046 | Weinstein et al. | Aug 2000 | A |
6102885 | Bass | Aug 2000 | A |
6106516 | Bmassengill | Aug 2000 | A |
6110162 | Sussman et al. | Aug 2000 | A |
6113722 | Hoffman et al. | Sep 2000 | A |
6126682 | Sharkey et al. | Oct 2000 | A |
6130671 | Argiro | Oct 2000 | A |
6139571 | Fuller et al. | Oct 2000 | A |
6149620 | Baker et al. | Nov 2000 | A |
6156036 | Sussman et al. | Dec 2000 | A |
6159194 | Eggers et al. | Dec 2000 | A |
6162232 | Shadduck | Dec 2000 | A |
6168594 | LaFontaine et al. | Jan 2001 | B1 |
6174308 | Goble et al. | Jan 2001 | B1 |
6179805 | Sussman et al. | Jan 2001 | B1 |
6190381 | Olsen et al. | Feb 2001 | B1 |
6194066 | Hoffman | Feb 2001 | B1 |
6196989 | Padget et al. | Mar 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6206848 | Sussman et al. | Mar 2001 | B1 |
6210404 | Shadduck | Apr 2001 | B1 |
6210405 | Goble et al. | Apr 2001 | B1 |
6219059 | Argiro | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6231567 | Rizoiu et al. | May 2001 | B1 |
6235020 | Cheng et al. | May 2001 | B1 |
6238391 | Olsen et al. | May 2001 | B1 |
6254597 | Rizoiu et al. | Jul 2001 | B1 |
6261286 | Goble et al. | Jul 2001 | B1 |
6261311 | Sharkey et al. | Jul 2001 | B1 |
6264650 | Hovda et al. | Jul 2001 | B1 |
6264651 | Underwood et al. | Jul 2001 | B1 |
6264654 | Swartz et al. | Jul 2001 | B1 |
6277112 | Underwood et al. | Aug 2001 | B1 |
6283910 | Bradshaw et al. | Sep 2001 | B1 |
6283961 | Underwood et al. | Sep 2001 | B1 |
6283989 | Laufer et al. | Sep 2001 | B1 |
6287274 | Sussman et al. | Sep 2001 | B1 |
6290715 | Sharkey et al. | Sep 2001 | B1 |
6296636 | Cheng et al. | Oct 2001 | B1 |
6296638 | Davison et al. | Oct 2001 | B1 |
6299633 | Laufer | Oct 2001 | B1 |
6300150 | Venkatasubramanian | Oct 2001 | B1 |
6312408 | Eggers et al. | Nov 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6315755 | Sussman | Nov 2001 | B1 |
6319222 | Andrew et al. | Nov 2001 | B1 |
6327505 | Medhkour et al. | Dec 2001 | B1 |
6331171 | Cohen | Dec 2001 | B1 |
6355032 | Hovda et al. | Mar 2002 | B1 |
6375635 | Moutafis et al. | Apr 2002 | B1 |
6379350 | Sharkey et al. | Apr 2002 | B1 |
6391025 | Weinstein et al. | May 2002 | B1 |
6394949 | Crowley et al. | May 2002 | B1 |
6394996 | Lawrence et al. | May 2002 | B1 |
6398759 | Sussman et al. | Jun 2002 | B1 |
6398775 | Perkins et al. | Jun 2002 | B1 |
6409723 | Edwards | Jun 2002 | B1 |
6416508 | Eggers et al. | Jul 2002 | B1 |
6458231 | Wapner et al. | Oct 2002 | B1 |
6461350 | Underwood et al. | Oct 2002 | B1 |
6464694 | Massengill | Oct 2002 | B1 |
6464695 | Hovda et al. | Oct 2002 | B2 |
6468270 | Hovda et al. | Oct 2002 | B1 |
6468274 | Alleyne et al. | Oct 2002 | B1 |
6468313 | Claeson et al. | Oct 2002 | B1 |
6482201 | Olsen et al. | Nov 2002 | B1 |
6482202 | Goble et al. | Nov 2002 | B1 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6500173 | Underwood et al. | Dec 2002 | B2 |
6508816 | Shadduck | Jan 2003 | B2 |
6517568 | Sharkey et al. | Feb 2003 | B1 |
6522930 | Schaer et al. | Feb 2003 | B1 |
6527761 | Soltesz et al. | Mar 2003 | B1 |
6527766 | Bair | Mar 2003 | B1 |
6540741 | Underwood et al. | Apr 2003 | B1 |
6544211 | Andrew et al. | Apr 2003 | B1 |
6544248 | Bass | Apr 2003 | B1 |
6547810 | Sharkey et al. | Apr 2003 | B1 |
6558379 | Batchelor et al. | May 2003 | B1 |
6569146 | Werner et al. | May 2003 | B1 |
6575929 | Sussman et al. | Jun 2003 | B2 |
6575968 | Eggers et al. | Jun 2003 | B1 |
6579270 | Sussman et al. | Jun 2003 | B2 |
6582423 | Thapliyal et al. | Jun 2003 | B1 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6588613 | Pechenik et al. | Jul 2003 | B1 |
6589201 | Sussman et al. | Jul 2003 | B1 |
6589204 | Sussman et al. | Jul 2003 | B1 |
6592594 | Rimbaugh et al. | Jul 2003 | B2 |
6595990 | Weinstein et al. | Jul 2003 | B1 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6602248 | Sharps et al. | Aug 2003 | B1 |
6605087 | Swartz et al. | Aug 2003 | B2 |
6610043 | Ingenito | Aug 2003 | B1 |
6620130 | Ginsburg | Sep 2003 | B1 |
6620155 | Underwood et al. | Sep 2003 | B2 |
6623444 | Babaev | Sep 2003 | B2 |
6632193 | Davison et al. | Oct 2003 | B1 |
6632220 | Eggers et al. | Oct 2003 | B1 |
6634363 | Danek et al. | Oct 2003 | B1 |
6648847 | Sussman et al. | Nov 2003 | B2 |
6652594 | Francis et al. | Nov 2003 | B2 |
6653525 | Ingenito et al. | Nov 2003 | B2 |
6659106 | Hovda et al. | Dec 2003 | B1 |
6669685 | Rizoiu et al. | Dec 2003 | B1 |
6669694 | Shadduck | Dec 2003 | B2 |
6676628 | Sussman et al. | Jan 2004 | B2 |
6676629 | Andrew et al. | Jan 2004 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6679879 | Shadduck | Jan 2004 | B2 |
6682520 | Ingenito | Jan 2004 | B2 |
6682543 | Barbut et al. | Jan 2004 | B2 |
6692494 | Cooper et al. | Feb 2004 | B1 |
6695839 | Sharkey et al. | Feb 2004 | B2 |
6699212 | Kadziauskas et al. | Mar 2004 | B1 |
6699244 | Carranza et al. | Mar 2004 | B2 |
6712811 | Underwood et al. | Mar 2004 | B2 |
6712812 | Roschak et al. | Mar 2004 | B2 |
6719738 | Mehier | Apr 2004 | B2 |
6719754 | Underwood et al. | Apr 2004 | B2 |
6723064 | Babaev | Apr 2004 | B2 |
6726684 | Woloszko et al. | Apr 2004 | B1 |
6726708 | Lasheras | Apr 2004 | B2 |
6746447 | Davison et al. | Jun 2004 | B2 |
6755794 | Soukup | Jun 2004 | B2 |
6758846 | Goble et al. | Jul 2004 | B2 |
6763836 | Tasto et al. | Jul 2004 | B2 |
6764487 | Mulier et al. | Jul 2004 | B2 |
6766202 | Underwood et al. | Jul 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6770071 | Woloszko et al. | Aug 2004 | B2 |
6772012 | Woloszko et al. | Aug 2004 | B2 |
6776765 | Soukup et al. | Aug 2004 | B2 |
6780180 | Goble et al. | Aug 2004 | B1 |
6805130 | Tasto et al. | Oct 2004 | B2 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6832996 | Woloszko et al. | Dec 2004 | B2 |
6837884 | Woloszko | Jan 2005 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6852108 | Barry et al. | Feb 2005 | B2 |
6860847 | Alferness et al. | Mar 2005 | B2 |
6860868 | Sussman et al. | Mar 2005 | B1 |
6875194 | MacKool | Apr 2005 | B2 |
6896674 | Wolosko et al. | May 2005 | B1 |
6896675 | Leung et al. | May 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6901927 | Deem et al. | Jun 2005 | B2 |
6904909 | Andreas et al. | Jun 2005 | B2 |
6907881 | Suki et al. | Jun 2005 | B2 |
6911028 | Shadduck | Jun 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6921385 | Clements et al. | Jul 2005 | B2 |
6929640 | Underwood et al. | Aug 2005 | B1 |
6949096 | Davison et al. | Sep 2005 | B2 |
6955675 | Jain | Oct 2005 | B2 |
6960182 | Moutafis et al. | Nov 2005 | B2 |
6962584 | Stone et al. | Nov 2005 | B1 |
6972014 | Eum et al. | Dec 2005 | B2 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
6986769 | Nelson et al. | Jan 2006 | B2 |
6991028 | Comeaux et al. | Jan 2006 | B2 |
6991631 | Wolosko et al. | Jan 2006 | B2 |
7022088 | Keast et al. | Apr 2006 | B2 |
7031504 | Argiro et al. | Apr 2006 | B1 |
7083612 | Littrup et al. | Aug 2006 | B2 |
7094249 | Broome et al. | Aug 2006 | B1 |
7128748 | Mooradian et al. | Oct 2006 | B2 |
7136064 | Zuiderveld | Nov 2006 | B2 |
7144402 | Kuester, III | Dec 2006 | B2 |
7144588 | Oray et al. | Dec 2006 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7192400 | Campbell et al. | Mar 2007 | B2 |
7233820 | Gilboa | Jun 2007 | B2 |
7235070 | Vanney | Jun 2007 | B2 |
7311708 | McClurken | Dec 2007 | B2 |
7335195 | Mehier | Feb 2008 | B2 |
7347859 | Garabedian et al. | Mar 2008 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7549987 | Shadduck | Jun 2009 | B2 |
7585295 | Ben-Nun | Sep 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7674259 | Shadduck | Mar 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7853333 | Demarais | Dec 2010 | B2 |
7873417 | Demarais et al. | Jan 2011 | B2 |
7892229 | Shadduck et al. | Feb 2011 | B2 |
7937143 | Demarais et al. | May 2011 | B2 |
7993323 | Barry et al. | Aug 2011 | B2 |
8016823 | Shadduck | Sep 2011 | B2 |
8131371 | Demarals et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8145316 | Deem et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
8187269 | Shadduck et al. | May 2012 | B2 |
8192424 | Woloszko | Jun 2012 | B2 |
8313485 | Shadduck | Nov 2012 | B2 |
8444636 | Shadduck et al. | May 2013 | B2 |
8574226 | Shadduck | Nov 2013 | B2 |
8579888 | Hoey et al. | Nov 2013 | B2 |
8579892 | Hoey et al. | Nov 2013 | B2 |
8579893 | Hoey | Nov 2013 | B2 |
20010020167 | Woloszko et al. | Sep 2001 | A1 |
20010029370 | Hodva et al. | Oct 2001 | A1 |
20010037106 | Shadduck | Nov 2001 | A1 |
20020049438 | Sharkey et al. | Apr 2002 | A1 |
20020077516 | Flanigan | Jun 2002 | A1 |
20020078956 | Sharpe et al. | Jun 2002 | A1 |
20020082667 | Shadduck | Jun 2002 | A1 |
20020095152 | Ciarrocca et al. | Jul 2002 | A1 |
20020111386 | Sekins et al. | Aug 2002 | A1 |
20020128638 | Chauvet et al. | Sep 2002 | A1 |
20020133147 | Marchitto et al. | Sep 2002 | A1 |
20020151917 | Barry | Oct 2002 | A1 |
20020161326 | Sussman et al. | Oct 2002 | A1 |
20020173815 | Hogendijk et al. | Nov 2002 | A1 |
20020177846 | Mulier et al. | Nov 2002 | A1 |
20020193789 | Underwood et al. | Dec 2002 | A1 |
20030028189 | Woloszko et al. | Feb 2003 | A1 |
20030040742 | Underwood et al. | Feb 2003 | A1 |
20030097126 | Woloszko et al. | May 2003 | A1 |
20030097129 | Davison et al. | May 2003 | A1 |
20030099279 | Venkatasubramanian et al. | May 2003 | A1 |
20030109869 | Shadduck | Jun 2003 | A1 |
20030130655 | Woloszko et al. | Jul 2003 | A1 |
20030130738 | Hovda et al. | Jul 2003 | A1 |
20030144654 | Hilal | Jul 2003 | A1 |
20030158545 | Hovda et al. | Aug 2003 | A1 |
20030163178 | Davison et al. | Aug 2003 | A1 |
20030181922 | Alferness | Sep 2003 | A1 |
20030212394 | Pearson et al. | Nov 2003 | A1 |
20030212395 | Woloszko et al. | Nov 2003 | A1 |
20030225364 | Kraft et al. | Dec 2003 | A1 |
20040024398 | Hovda et al. | Feb 2004 | A1 |
20040024399 | Sharps et al. | Feb 2004 | A1 |
20040031494 | Danek et al. | Feb 2004 | A1 |
20040038868 | Ingenito | Feb 2004 | A1 |
20040047855 | Ingenito | Mar 2004 | A1 |
20040049180 | Sharps et al. | Mar 2004 | A1 |
20040054366 | Davison et al. | Mar 2004 | A1 |
20040055606 | Hendricksen et al. | Mar 2004 | A1 |
20040068256 | Rizoiu et al. | Apr 2004 | A1 |
20040068306 | Shadduck | Apr 2004 | A1 |
20040087937 | Eggers et al. | May 2004 | A1 |
20040116922 | Hovda et al. | Jun 2004 | A1 |
20040193150 | Sharkey et al. | Sep 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040230190 | Dahla et al. | Nov 2004 | A1 |
20040254532 | Mehier | Dec 2004 | A1 |
20050004634 | Ricart et al. | Jan 2005 | A1 |
20050010205 | Hovda et al. | Jan 2005 | A1 |
20050070894 | McClurken | Mar 2005 | A1 |
20050119650 | Sanders et al. | Jun 2005 | A1 |
20050166925 | Wilson et al. | Aug 2005 | A1 |
20050171582 | Matlock | Aug 2005 | A1 |
20050187543 | Underwood et al. | Aug 2005 | A1 |
20050215991 | Altman et al. | Sep 2005 | A1 |
20050222485 | Shaw et al. | Oct 2005 | A1 |
20050228423 | Khashayar et al. | Oct 2005 | A1 |
20050228424 | Khashayar et al. | Oct 2005 | A1 |
20050240171 | Forrest | Oct 2005 | A1 |
20050267467 | Paul et al. | Dec 2005 | A1 |
20050267468 | Truckai et al. | Dec 2005 | A1 |
20050283143 | Rizoiu | Dec 2005 | A1 |
20060004400 | McGurk et al. | Jan 2006 | A1 |
20060047291 | Barry | Mar 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060100619 | McClurken et al. | May 2006 | A1 |
20060130830 | Barry | Jun 2006 | A1 |
20060135955 | Shadduck | Jun 2006 | A1 |
20060142783 | Lewis et al. | Jun 2006 | A1 |
20060161233 | Barry et al. | Jul 2006 | A1 |
20060200076 | Gonzalez et al. | Sep 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060224154 | Shadduck et al. | Oct 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20070032785 | Diederich et al. | Feb 2007 | A1 |
20070036417 | Argiro et al. | Feb 2007 | A1 |
20070091087 | Zuiderveld | Apr 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070129761 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20080033493 | Deckman et al. | Feb 2008 | A1 |
20080097429 | McClurken | Apr 2008 | A1 |
20080103566 | Mehier | May 2008 | A1 |
20080110457 | Barry et al. | May 2008 | A1 |
20080114297 | Barry et al. | May 2008 | A1 |
20080125747 | Prokop | May 2008 | A1 |
20080132826 | Shadduck et al. | Jun 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20090030412 | Willis et al. | Jan 2009 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090054871 | Sharkey et al. | Feb 2009 | A1 |
20090062873 | Wu et al. | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090105702 | Shadduck | Apr 2009 | A1 |
20090105703 | Shadduck | Apr 2009 | A1 |
20090125009 | Zikorus et al. | May 2009 | A1 |
20090149846 | Hoey et al. | Jun 2009 | A1 |
20090216220 | Hoey et al. | Aug 2009 | A1 |
20090306640 | Glaze et al. | Dec 2009 | A1 |
20090312753 | Shadduck | Dec 2009 | A1 |
20100076416 | Hoey et al. | Mar 2010 | A1 |
20100094270 | Sharma | Apr 2010 | A1 |
20100114083 | Sharma | May 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100160905 | Shadduck | Jun 2010 | A1 |
20100168731 | Wu et al. | Jul 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100174282 | Demarais et al. | Jul 2010 | A1 |
20100179528 | Shadduck et al. | Jul 2010 | A1 |
20100185189 | Hoey | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100204688 | Hoey et al. | Aug 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100249773 | Clark et al. | Sep 2010 | A1 |
20100262133 | Hoey et al. | Oct 2010 | A1 |
20100268307 | Demarais et al. | Oct 2010 | A1 |
20110060324 | Wu et al. | Mar 2011 | A1 |
20110077628 | Hoey et al. | Mar 2011 | A1 |
20110112400 | Emery et al. | May 2011 | A1 |
20110118717 | Shadduck | May 2011 | A1 |
20110166499 | Demarais et al. | Jul 2011 | A1 |
20110178570 | Demarais | Jul 2011 | A1 |
20110200171 | Beetel et al. | Aug 2011 | A1 |
20110202098 | Demarais et al. | Aug 2011 | A1 |
20110208096 | Demarais et al. | Aug 2011 | A1 |
20110257564 | Demarais et al. | Oct 2011 | A1 |
20110264011 | Wu et al. | Oct 2011 | A1 |
20110264075 | Leung et al. | Oct 2011 | A1 |
20110264090 | Shadduck et al. | Oct 2011 | A1 |
20120065632 | Shadduck | Mar 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120101538 | Ballakur et al. | Apr 2012 | A1 |
20120116382 | Ku et al. | May 2012 | A1 |
20120116383 | Mauch et al. | May 2012 | A1 |
20120116486 | Naga et al. | May 2012 | A1 |
20120130289 | Demarais et al. | May 2012 | A1 |
20120130345 | Levin et al. | May 2012 | A1 |
20120130359 | Turovskiy | May 2012 | A1 |
20120130360 | Buckley et al. | May 2012 | A1 |
20120130458 | Ryba et al. | May 2012 | A1 |
20120136344 | Buckley et al. | May 2012 | A1 |
20120136350 | Goshgarian et al. | May 2012 | A1 |
20120136417 | Buckley et al. | May 2012 | A1 |
20120136418 | Buckley et al. | May 2012 | A1 |
20120143181 | Demarais et al. | Jun 2012 | A1 |
20120143293 | Mauch et al. | Jun 2012 | A1 |
20120150267 | Buckley et al. | Jun 2012 | A1 |
20120158104 | Huynh et al. | Jun 2012 | A1 |
20120172837 | Demarais et al. | Jul 2012 | A1 |
20120197198 | Demarais et al. | Aug 2012 | A1 |
20120197252 | Deem et al. | Aug 2012 | A1 |
20120259271 | Shadduck et al. | Oct 2012 | A1 |
20130079772 | Shadduck | Mar 2013 | A1 |
20130116683 | Shadduck et al. | May 2013 | A1 |
20130237978 | Shadduck et al. | Sep 2013 | A1 |
20140018890 | Hoey et al. | Jan 2014 | A1 |
20140025057 | Hoey et al. | Jan 2014 | A1 |
20140031805 | Shadduck | Jan 2014 | A1 |
Number | Date | Country |
---|---|---|
WO 0011927 | Mar 2000 | WO |
WO 0029055 | May 2000 | WO |
WO 02069821 | Sep 2002 | WO |
WO 03070302 | Aug 2003 | WO |
WO 03086498 | Oct 2003 | WO |
WO 2005025635 | Mar 2005 | WO |
WO 2005102175 | Nov 2005 | WO |
WO 2006003665 | Jan 2006 | WO |
WO 2006055695 | May 2006 | WO |
WO 2009009398 | Jan 2009 | WO |
Entry |
---|
Coda, et al., “Effects of pulmonary reventilation on gas exchange after cryolytic disobstruction of endobronchial tumors” Minerva Medical, vol. 72, pp. 1627-1631, Jun. 1981 (with English translation). |
Fishman et al., “A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema,” N Engl J Med, vol. 348, No. 21, pp. 2059-2073, May 22, 2003. |
Homasson, et al., “Bronchoscopic cryotherapy for airway strictures caused by tumors” Chest, vol. 90, No. 2, pp. 159-164, Aug. 1986. |
Li, K., “Efficient optimal net surface detection for image segmentation—from theory to practice” M.Sc. Thesis, The University of Iowa, 2003. |
Marasso, et al., “Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis,” Chest, vol. 103, No. 2, pp. 472-474, Feb. 1993. |
Marasso, et al., “Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique,” Thorax, vol. 53, pp. 106-109, 1998. |
Mathur et al., “Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction,” Chest, vol. 110, No. 3, pp. 718-723. Sep. 1996. |
Morice et al. “Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction,” Chest, vol. 119, No. 3, pp. 781-787, Mar. 2001. |
Moulding et al., “Preliminary studies for achieving transcervical oviduct occlusion by hot water or low-pressure stream,” Advancesin Planned Parenthood, vol. 12, No. 2; pp. 79-85, 1977. |
Quin, J., “Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, pp. 407-412, Jul. 1995. |
Sutedja, et al., “Bronchoscopic treatment of lung tumors,” Elsevier, Lung Cancer, 11, pp. 1-17, 1994. |
Tschirren et al.; “Intrathoracic airway trees: segmentation and airway morphology analysis from low-dose CT scans;” IEEE Trans. Med. Imaging, vol. 24, No. 12; pp. 1529-1539, Dec. 2005. |
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Ph.D. Thesis, The University of Iowa, 231 pages, Aug. 2003. |
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Slides from Ph.D. defense, University of Iowa, 130 pages, Aug. 2003. |
Unger, M. et al. “Monolithic Microfabricated Valves and Pumps by Multilayer Soft Lithography,” Science, vol. 288, pp. 113-116, Apr. 7, 2000, accessed at http://web.mit.edu/thorsen/www/113.pdf. |
Xia, Y. et al. “Soft Lithography,” Annu. Rev. Mater. Sci., vol. 28, pp. 153-184, 1998, accessed at http://www.bwfoundry.com/xia.pdf. |
Number | Date | Country | |
---|---|---|---|
20110160648 A1 | Jun 2011 | US |
Number | Date | Country | |
---|---|---|---|
61291315 | Dec 2009 | US |